Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Pfizer Inc. raised the lower end of its earnings forecast for the year and reiterated its sales expectations despite unfavorable currency trends. The drugmaker continues to project its new Covid ...

The pharmaceutical giant also hiked its full-year outlook and now expects to book adjusted earnings per share of $2.75 to $2.95, up from its previous guidance of 2.45 to $2.65 per share.

Pfizer (PFE) reported solid fourth-quarter results but provided lower-than-expected guidance for 2023. We don’t expect any major changes to our Pfizer fair value estimate, and the stock looks ...

Pfizer (PFE) is set to release its Q4 2023 results amid rising bearish bets on its earnings outlook due to headwinds against its COVID-19 franchise. Read more here.

Pfizer missed first quarter earnings Thursday amid a volatile macro environment. ... Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3.

Pfizer said Tuesday it now expects 2024 adjusted earnings between $2.45 a share to $2.65 a share, 30 cents higher at the midpoint than its prior projection.

Pfizer shares rose over 1% in pre-market trading Tuesday after the pharmaceutical giant beat Q4 earnings and revenue estimates while reaffirming its 2025 financial guidance.Q4 Results. Non-GAAP ...

Pfizer (PFE) delivered earnings and revenue surprises of 43.75% and 0.88%, ... but one reliable measure that can help investors address this is the company's earnings outlook.